8I8 Stock Chart & Stats
€0.42
€0.01(2.90%)
At close: 4:00 PM EDT
€0.42
€0.01(2.90%)
Day’s Range― - ―
52-Week Range€0.36 - €0.71
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€268.76M
Enterprise Value€199.41
Total Cash (Recent Filing)€1.96B
Total Debt (Recent Filing)€1.68B
Price to Earnings (P/E)10.6
Beta<0.01
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.59
Shares Outstanding581,326,300
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)6.10
Price to Sales (P/S)2.63
P/FCF Ratio14.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.4
Revenue Forecast (FY)€8.61B
Bulls Say, Bears Say
Bulls Say
Broad-based GrowthStrong growth across revenue, testing volumes, and patients indicates expanding demand and deeper utilization of IDH’s diagnostic platform. This supports operating leverage, strengthens the company’s provider and patient reach, and provides a durable base for continued earnings growth.
Scalable ProfitabilityProfit growth outpaced revenue growth while EBITDA remained resilient despite investment in Saudi Arabia and radiology. The combination of scale, procurement optimization, and disciplined costs suggests that IDH can sustain attractive margins as its network and service mix continue to expand.
Network Expansion And Service BreadthA rapidly expanding Egyptian footprint improves patient access, referral reach, and utilization across the core laboratory network. Growth in radiology and radiotherapy also broadens the company’s capabilities, supporting cross-selling and reducing reliance on a narrower diagnostic offering over time.
Bears Say
Working-capital PressureRising receivables and inventory absorb cash even while reported earnings grow, increasing the gap between accounting profit and available funds. Continued working-capital investment could constrain funding flexibility and make cash generation less predictable during the next several quarters.
Geopolitical ExposureIDH operates across markets exposed to regional instability, which can affect patient volumes, economic activity, and operating continuity. The constrained Sudan business demonstrates that geopolitical conditions can directly limit network productivity and create an ongoing drag on group performance.
Saudi Business Below Break-evenSaudi expansion offers long-term growth potential but currently requires investment before contributing positively to earnings. Further branch openings may extend the period of losses and place pressure on group margins and cash resources until utilization reaches a sustainable break-even level.
Integrated Diagnostics Holdings News
8I8 FAQ
What was Integrated Diagnostics Holdings PLC’s price range in the past 12 months?
Integrated Diagnostics Holdings PLC lowest stock price was €0.36 and its highest was €0.71 in the past 12 months.
What is Integrated Diagnostics Holdings PLC’s market cap?
Integrated Diagnostics Holdings PLC’s market cap is €268.76M.
When is Integrated Diagnostics Holdings PLC’s upcoming earnings report date?
Integrated Diagnostics Holdings PLC’s upcoming earnings report date is Nov 12, 2026 which is in 50 days.
How were Integrated Diagnostics Holdings PLC’s earnings last quarter?
Integrated Diagnostics Holdings PLC released its earnings results on Nov 14, 2024. The company reported €0.007 earnings per share for the quarter.
Is Integrated Diagnostics Holdings PLC overvalued?
According to Wall Street analysts Integrated Diagnostics Holdings PLC’s price is currently Overvalued.
Does Integrated Diagnostics Holdings PLC pay dividends?
Integrated Diagnostics Holdings PLC does not currently pay dividends.
What is Integrated Diagnostics Holdings PLC’s EPS estimate?
Integrated Diagnostics Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Integrated Diagnostics Holdings PLC have?
Integrated Diagnostics Holdings PLC has 581,326,300 shares outstanding.
What happened to Integrated Diagnostics Holdings PLC’s price movement after its last earnings report?
Integrated Diagnostics Holdings PLC reported an EPS of €0.007 in its last earnings report. Following the earnings report the stock price went down -3.774%.
Which hedge fund is a major shareholder of Integrated Diagnostics Holdings PLC?
Currently, no hedge funds are holding shares in DE:8I8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Integrated Diagnostics Holdings Stock Smart Score
Company Description
Integrated Diagnostics Holdings PLC
Integrated Diagnostics Holdings plc (IDHC.L) functions as a leading consumer healthcare enterprise, offering a wide array of medical diagnostic services directly to its clientele. The company's comprehensive service catalog features around 2,000 distinct diagnostic examinations, spanning specialized fields such as immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, cytogenetics, histopathology, and radiology. Geographically, IDHC has established operations across Egypt, Jordan, Sudan, and Nigeria. As of December 30, 2021, its infrastructure included an extensive network of 452 laboratory branches. The organization was founded in 1979 and maintains its corporate headquarters in Saint Helier, Jersey.
Technical Analysis
Bioventix
―
EKF Diagnostics Holdings
―
Genedrive
―
Omega Diagnostics
―
Abingdon Health PLC
―